Ventilation and Perfusion in Asthmatics
Recruiting · NCT07426458 · Interventional (participants receive a specific treatment) · Lead sponsor: University of Miami
View the official record on ClinicalTrials.gov →Interventions studied
Albuterol SulfateAlbuterol-Budesonide
What this trial is about
Assess regional changes to perfusion and ventilation from inhaled corticosteroid (ICS) and Fast-acting beta-antagonist (FABA) among adult asthmatics using radiographically derived estimates of regional ventilation (V-distribution), ventilation defect percentage (VDP), and ventilation heterogeneity (VH).
Who can take part
Age range
18 Years to 75 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 4
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Physician diagnosis of asthma
- Baseline Forced Expiratory Volume in 1 Second (FEV1) \< 80% of predicted, with reversibility (10%) on post-bronchodilator spirometry
- Adults, 18-75 years of age
- Long-term inhaled controller medication consisting of or including an Inhaled corticosteroids (ICS) at a steady dose for at least 3 months before enrollment
Exclusion criteria
- Current cigarette smoking or a past history of \>10 pack-year smoking
- Current nicotine vaping
- Pregnant and breast-feeding women
- Respiratory infection within 4 weeks of proposed study date
- Forced Expiratory Volume in 1 Second (FEV1) \< 50%
- Inhaled corticosteroids (ICS)/fast-acting beta agonist (FABA) intolerance
- Use of beta-blockers
- Use of systemic glucocorticosteroids or oral methyl-xanthines within 30 days of planned study visit.
Where it is running
1 location listed across 1 US state.
- University of Miami - Converge Miami - Miami, Florida, United States